Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON) Oculis also aims to complete an IND submission for OCS-05 in the
U.S. stock futures were slightly higher this morning, with the Dow Jones futures gaining around 15 points on Thursday.
Shares of FLJ Group Limited(NASDAQ: FLJ) rose sharply in pre-market trading.
LEOPARD trial initiation follows recent positive data from OCS-01 eye drops from the Stage 1 Phase 3 DIAMOND trial in patients with Diabetic Macular Edema (DME)
Cystoid Macular Edema (CME) can result from